Company news
Rezolute, Inc. news in 2022
Rezolute, Inc.'s news releases, calls and decks from 2022, newest first.
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 14, 2022
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
November 8, 2022
Rezolute to Present at the Jefferies London Healthcare Conference
October 31, 2022
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
October 19, 2022
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
September 14, 2022
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
September 6, 2022
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
May 31, 2022
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 11, 2022
Rezolute to Host Corporate Update Call on May 4, 2022
May 3, 2022
Rezolute, Inc. Announces Closing of Registered Direct Offering
May 3, 2022
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
April 30, 2022
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
April 30, 2022
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
April 25, 2022
Rezolute Joins the Rare Disease Company Coalition
March 28, 2022
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
March 22, 2022
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
February 21, 2022
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
February 8, 2022
Decks in 2022
- Technical Presentation (May 2022)
Technical · 18 slides · May 2, 2022
- Technical Presentation (2022)
Technical · 13 slides · 2022